NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ: VCYT) shares fell after the Company's November 4, 2026 third-quarter report stated that "Decipher Prostate volume was below our expectations." Needham reportedly cut its price target by $23, from $69 to $46. If you bought VCYT and are now holding losses, this investigation concerns you. Shareholders who lost money are encouraged to submit their Veracyte loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Decipher Prostate is Veracyte's genomic test used in prostate cancer treatment decisions. In the same November 4 release, the Company narrowed its full-year 2026 revenue guidance to between $590 million and $593 million, down from between $590 million and $596 million.
The November 4 shortfall followed an earlier reduction. On July 30, 2026, CEO Marc Stapley said Veracyte was lowering its full-year Decipher volume expectations by slightly more than 1,000 tests, primarily in the low-risk setting, to roughly 19,000 to 21,000 tests per year. That guidance has now been slashed by a further 4,000 to 9,000 additional tests per year, to a rough 12,000 to 15,000. Levi & Korsinsky is investigating potential securities law violations on behalf of Veracyte investors.
Veracyte investors with losses can request a no-cost review of their VCYT losses or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured billions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the VCYT Investigation
Q: Who is conducting the VCYT investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased Veracyte (NASDAQ: VCYT) securities. The firm is nationally recognized and has been ranked in the ISS Top 50 for seven consecutive years.
Q: Who is eligible to participate in the VCYT investigation? A: Investors who purchased VCYT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do VCYT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my VCYT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought VCYT and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
